SCHEMBL6722073

SCHEMBL6722073

CC(C)(O)CCOc1ccc2[nH]cc(C(=O)Nc3ccccn3)c2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
GAA P10253 2/20 0.42
TP53 P04637 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
HTR1A P08908 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
HTR1F P30939 1/20 0.41
GRM5 P41594 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 1/20 0.40
SGMS2 Q8NHU3 1/20 0.39
HTR2C P28335 1/20 0.38
ALDH1A1 P00352 2/20 0.38
FGFR4 P22455 1/20 0.38
CHRNB2 P17787 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6728799 0.95 NPC1 (0.41) NPC1RAB9AMEN1KMT2AGAA
SCHEMBL6722139 0.86 RXFP1 (0.54) NPC1RAB9AMEN1KMT2AGAA
SCHEMBL6726671 0.85 PIM1 (0.43) NPC1RAB9AMEN1KMT2AGAA
SCHEMBL6722035 0.85 HTR2C (0.44) NPC1RAB9AMEN1KMT2AGAA
SCHEMBL6727000 0.85 RXFP1 (0.44) NPC1RAB9AMEN1KMT2AGAA
SCHEMBL6726254 0.85 NPC1 (0.42) NPC1RAB9AMEN1KMT2AGAA
SCHEMBL6734017 0.84 RXFP1 (0.43) NPC1RAB9AMEN1KMT2AGAA
SCHEMBL6726955 0.84 NPC1 (0.41) NPC1RAB9AMEN1KMT2AGAA
SCHEMBL6671344 0.84 NPC1 (0.54) NPC1RAB9AMEN1KMT2AGAA
SCHEMBL6729649 0.83 HTR2C (0.47) NPC1RAB9AMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673811-B1 TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS NEUROGEN CORPORATION 2004-01-06 US claimed
US-6673811-B1 TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS NEUROGEN CORPORATION 2004-01-06 US disclosed